Nektar Therapeutics (NKTR) Free Cash Flow Growth (3y) (2013 - 2026)
Nektar Therapeutics (NKTR) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Nektar Therapeutics | 1.75 Bn | 1.18 Bn | 3.16 Mn | 5.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.40% |
| Dec 31, 2025 | -3.73% |
| Sep 30, 2025 | 16.21% |
| Jun 30, 2025 | 15.46% |
| Mar 31, 2025 | 19.09% |
| Dec 31, 2024 | 33.33% |
| Sep 30, 2024 | 24.61% |
| Jun 30, 2024 | 23.96% |
| Mar 31, 2024 | 15.62% |
| Dec 31, 2023 | 22.19% |
| Sep 30, 2023 | 8.25% |
| Jun 30, 2023 | 15.80% |
| Mar 31, 2023 | 12.81% |
| Dec 31, 2022 | 23.28% |
| Sep 30, 2022 | -3.95% |
| Jun 30, 2022 | -4.94% |
| Mar 31, 2022 | -2.29% |
| Dec 31, 2021 | -7.64% |
| Sep 30, 2021 | -12.43% |
| Jun 30, 2021 | -27.86% |